The intake of antioxidants has increased in the last years in order to treat some pathologies associated with oxidative stress such as cancer, diabetes mellitus, atherosclerosis, myocardial infarction, acute pancreatitis, Parkinson's and Alzheimer's disease among others. In colorectal cancer, a widely antineoplastic drug used is the fluorinated uracil molecule 5-Fluorouracile (5-FU). The aim of this study is to assess the antioxidant capacity observed by the inhibition of lipid peroxidation by 5-FU and other fluorinated uracil derivates: 6-[Difluoro(phenyl)methyl]-3-(2,4,6-trifluorophenyl)pyrimidine-2,4(1H,3H)-dione (S-81), 3-[2-Chloroethyl]-6-[difluoro(phenyl)methyl]pyrimidine-2,4(1H,3H)-dione (S-86), 6-[Difluoro(phenyl)methyl]-3-(4-trifluoromethoxyphenyl)pyrimidine-2,4(1H,3H)-dione (S-123). The results showed a significant decrease in MDA production of 58.12% in S-86, 44.61% in S-123, 24.11% in 5-FU and 10.83% in S-81 in the sample with highest concentration (10µM). 5-FU also showed a Total Antioxidant Capacity of 0.68 Trolox Equivalent Antioxidant Capacity.
Previous Article in event Previous Article in congress
Next Article in event
Inhibition of Secretory Aspartyl Protease of Candida albicans by metabolites of Streptomyces chrestomyceticus strain ADP4Next Article in congress
Antioxidant activity of 5-FU and new fluorinated uracil derivates
Published: 16 November 2017 by MDPI in MOL2NET'17, Conference on Molecular, Biomedical & Computational Sciences and Engineering, 3rd ed. congress NIXMSM-03: North-Ibero-Am. Exp., Model. & Simul. Meth. Work., Valencia, Bilbao, Spain-Paraiba, Brasil-Miami, USA, 2017
Keywords: 5-Fluorouracile, antioxidants, fluorinated uracil derivates, MDA